Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity. Academic Article

abstract

• OBJECTIVES: The focus of the present research is to develop printlet formulations of pyrimethamine (PMT). METHODS: Printlets formulation of PMT were developed by screening design by varying laser scanning speed, Kollidon VA 64, polyvinylpyrrolidone, and disintegrant. RESULTS: Laser scanning speed, Kollidon VA, and disintegrant had statistically significant effect on hardness, disintegration time, and/or dissolution (p<0.05). Dissolution was almost 100% in 30min. X-ray powder diffraction indicated partial amorphous transformation of the crystalline drug. Pharmacokinetic and anti-toxoplasma activity profiles of the printlets and compressed tablets were superimposable with no statistical difference (p>0.05). CONCLUSION: Clinical performance of the printlets would be similar to the compressed tablets.

authors

• Khan, Mansoor
• Kuttolamadom, Mathew

published proceedings

• Expert Opin Drug Deliv

author list (cited authors)

• Rahman, Z., Khuroo, T., Mohamed, E. M., Dharani, S., Kayalar, C., Kuttolamadom, M. A., Sangar, L. O., & Khan, M. A.

citation count

• 0

complete list of authors

• Rahman, Ziyaur||Khuroo, Tahir||Mohamed, Eman M||Dharani, Sathish||Kayalar, Canberk||Kuttolamadom, Mathew A||Sangaré, Lamba Omar||Khan, Mansoor A

publication date

• February 2023

publisher

• Taylor & Francis  Publisher

keywords

• Anti-toxoplasma Activity
• Child
• Dissolution
• Excipients
• Humans
• PHASE TRANSFORMATION
• Pharmacokinetic
• Povidone
• Printlets
• Pyrimethamine
• Solubility
• Tablets
• Toxoplasma
• Toxoplasmosis

Digital Object Identifier (DOI)

• 10.1080/17425247.2023.2169272

start page

• 301

end page

• 311

volume

• 20

issue

• 2

URL

• http://dx.doi.org/10.1080/17425247.2023.2169272